Sign up to save your podcasts
Or
Share First Rounders
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
First Rounders
By Nature Biotechnology
First Rounders episodes
- First Rounder: Bill RutterNature Biotechnology spoke to Rutter about building out the labs at UCSF, sequencing the hepatitis C virus and his short stint in the Navy.53 min
- First Rounder: Stan CrookeStan Crooke is the founder, chairman and CEO of Isis Pharmaceuticals. Nature Biotechnology spoke with Crooke about his troubled youth, the crests and valleys of antisense, and the skills needed to be a good leader.
Hosted on Acast. See acast.com/privacy for more information.
1 hr 5 min - First Rounder: Stan CrookeStan Crooke is the founder, chairman and CEO of Isis Pharmaceuticals. Nature Biotechnology spoke with Crooke about his troubled youth, the crests and valleys of antisense, and the skills needed to be a good leader. For information regarding your data privacy, visit acast.com/privacy1 hr 5 min
- First Rounder: Stanley CrookeStan Crooke discusses his troubled youth, the crests and valleys of antisense, and the skills needed to be a good leader.1 hr 5 min
- First Rounder: Rachel KingRachel King is president and CEO of GlycoMimetics and former chairwoman of the Biotechnology Innovation Organization. Talking with Nature Biotechnology, King discusses gene therapy, how a CEO handles layoffs and growing up with chickens.
Hosted on Acast. See acast.com/privacy for more information.
59 min - First Rounder: Rachel KingRachel King is president and CEO of GlycoMimetics and former chairwoman of the Biotechnology Innovation Organization. Talking with Nature Biotechnology, King discusses gene therapy, how a CEO handles layoffs and growing up with chickens. For information regarding your data privacy, visit acast.com/privacy59 min
- First Rounder: Rachel KingRachel King is president and CEO of GlycoMimetics and former chairwoman of the Biotechnology Innovation Organization. Talking with Nature Biotechnology, King discusses gene therapy, how a CEO handles layoffs and growing up with chickens.59 min
- First Rounder: Colin GoddardColin Goddard is former CEO of OSI Pharmaceuticals, and current chairman and CEO of Coferon. His conversation with Nature Biotechnology details the history behind OSI's blockbuster drug Tarceva (erlotinib), the benefits of having a British accent in the United States and how to survive a hostile takeover.
Hosted on Acast. See acast.com/privacy for more information.
59 min - First Rounder: Colin GoddardColin Goddard is former CEO of OSI Pharmaceuticals, and current chairman and CEO of Coferon. His conversation with Nature Biotechnology details the history behind OSI's blockbuster drug Tarceva (erlotinib), the benefits of having a British accent in the United States and how to survive a hostile takeover. For information regarding your data privacy, visit acast.com/privacy59 min
- First Rounder: Colin GoddardColin Goddard is former CEO of OSI Pharmaceuticals, and current chairman and CEO of Coferon. His conversation with Nature Biotechnology details the history behind OSI's blockbuster drug Tarceva (erlotinib), the benefits of having a British accent in the United States and how to survive a hostile takeover.59 min
About First Rounders
From the publisher's feed
Nature Biotechnology's First Rounders podcast is a series of conversations with founders, financers and developers from biotech's past, present and future.
Hosted on Acast. See
href="https://acast.com/privacy" rel="noopener noreferrer">acast.com/privacy for more information.